DLX105 topical: Phase II data

A double-blind, placebo-controlled, Austrian and German Phase II trial in 59 patients with mild to moderate plaque psoriasis showed twice-daily topical 0.5% DLx10 5 for 4 weeks led to no significant clinical improvements. However, gene expression data from skin biopsies at day 14 showed that DLx10 5 significantly reduced TNF alpha and T helper type 17 (Th17) cytokines vs. placebo. Based on the data, Delenex said it expects to see clinical activity and an impact on PASI scores with longer treatment periods and with increased drug concentrations of DLx10 5 in the skin. DLx10 5 was well tolerated with no serious adverse events reported. Data were presented at the Dermatological Research meeting in Copenhagen. The company said decisions regarding next steps have yet to be made. ...